Atria Investments Inc Takes $330,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Atria Investments Inc purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, Holdings Channel reports. The fund purchased 3,005 shares of the medical equipment provider’s stock, valued at approximately $330,000.

Other hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 208 shares during the period. Signaturefd LLC raised its stake in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares during the last quarter. Nkcfo LLC acquired a new position in Lantheus in the second quarter valued at approximately $47,000. UMB Bank n.a. boosted its stake in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new stake in Lantheus during the 3rd quarter worth $51,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

NASDAQ LNTH opened at $90.52 on Friday. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The firm has a market cap of $6.29 billion, a P/E ratio of 14.97 and a beta of 0.51. The stock’s 50-day moving average is $103.43 and its 200-day moving average is $96.53.

Analyst Ratings Changes

A number of research firms have recently weighed in on LNTH. JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Truist Financial reissued a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $122.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.